Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Mernberger

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Plos Genetics|August 23, 2013
Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functionsKatharina Schlereth, Charlotte Heyl, Anna-Maria Krampitz, et al.
Cancers|October 13, 2021
Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated TumorsLeonie Gebauer, Andrea Nist, Marco Mernberger, et al.
Oncogene|December 15, 2021
p53 partial loss-of-function mutations sensitize to chemotherapyBoris Klimovich, Nastasja Merle, Michelle Neumann, et al.
Oncotarget|June 2, 2018
MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemiaMiriam Frech, Sabine Teichler, Christine Feld, et al.
Plos One|April 23, 2015
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for DifferentiationCornelia Brendel, Sabine Teichler, Axel Millahn, et al.
Cell Death & Disease|October 14, 2016
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistanceYvonne Voges, Martin Michaelis, Florian Rothweiler, et al.
Nucleic Acids Research|January 29, 2016
ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinomaAnne Catherine Bretz, Miriam P Gittler, Joël P Charles, et al.
Cancers|May 3, 2020
YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance SettingMartin Michaelis, Mark N Wass, Ian Reddin, et al.
Cytotherapy|December 3, 2014
Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiationPhilipp Nold, Holger Hackstein, Tabea Riedlinger, et al.
Nature|July 31, 2020
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenicEliran Kadosh, Irit Snir-Alkalay, Avanthika Venkatachalam, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Plos Genetics|August 23, 2013
Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functionsKatharina Schlereth, Charlotte Heyl, Anna-Maria Krampitz, et al.
Cancers|October 13, 2021
Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated TumorsLeonie Gebauer, Andrea Nist, Marco Mernberger, et al.
Oncogene|December 15, 2021
p53 partial loss-of-function mutations sensitize to chemotherapyBoris Klimovich, Nastasja Merle, Michelle Neumann, et al.
Oncotarget|June 2, 2018
MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemiaMiriam Frech, Sabine Teichler, Christine Feld, et al.
Plos One|April 23, 2015
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for DifferentiationCornelia Brendel, Sabine Teichler, Axel Millahn, et al.
Cell Death & Disease|October 14, 2016
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistanceYvonne Voges, Martin Michaelis, Florian Rothweiler, et al.
Nucleic Acids Research|January 29, 2016
ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinomaAnne Catherine Bretz, Miriam P Gittler, Joël P Charles, et al.
Cancers|May 3, 2020
YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance SettingMartin Michaelis, Mark N Wass, Ian Reddin, et al.
Cytotherapy|December 3, 2014
Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiationPhilipp Nold, Holger Hackstein, Tabea Riedlinger, et al.
Nature|July 31, 2020
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenicEliran Kadosh, Irit Snir-Alkalay, Avanthika Venkatachalam, et al.
Pageof 4